The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial.

ABSTRACT:

Importance

Improving treatment outcomes for smokers with major depressive disorder (MDD) can have significant public health implications.

Objective

To evaluate the safety and efficacy of smoking cessation pharmacotherapy among smokers with MDD.

Design

Secondary analysis of a randomized, double-blind, active- (nicotine patch) and placebo-controlled trial of 12 weeks of either varenicline or bupropion with a 12-week follow-up.

Participants

Community volunteers 18-75 years of age; smoke 10+ cigarettes/day; with clinically stable MDD (N = 2635) or no psychiatric disorder (N = 4028), from 140 sites in 16 countries.

Intervention

Twelve weeks of pharmacotherapy (placebo [PLA], nicotine replacement therapy [NRT], bupropion [BUP], varenicline [VAR]) plus brief ce

SUBMITTER: Cinciripini PM 

PROVIDER: S-EPMC9705120 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature